期刊文献+

β受体阻滞剂比索洛尔对老年原发性高血压患者骨代谢的影响 被引量:3

The effect of β blocker on bone metabolism of the elderly patients with hypertension
下载PDF
导出
摘要 目的观察β受体阻滞剂比索洛尔对老年原发性高血压患者骨质密度及骨折发生率的影响。方法选择老年男性原发性高血压患者150例,按是否服用β受体阻滞剂比索洛尔分为治疗组(85例,比索洛尔5 mg/d,连续服用3年)和对照组(65例)。分别比较两组血清钙、磷、碱性磷酸酶浓度;并分析骨密度及骨折发生率。结果治疗组血清钙、磷、碱性磷酸酶浓度与对照组比较,差异均无统计学意义(P>0.05);治疗组患者用药3年后骨折4例(4.7%),对照组患者3年后骨折7例(10.8%),治疗组较对照组骨折发生率虽有下降,但差异无统计学意义(P>0.05);与用药前骨密度比较,治疗组用药3年后骨密度明显增高[(1.04±0.11)g/cm^2vs(1.49±0.13)g/cm^2,P<0.05];与对照组3年后骨密度比较,治疗组用药3年后骨密度也明显增高[(1.06±0.12)g/cm^2vs(1.49±0.13)g/cm^3,P<0.05]。结论长期服用治疗剂量β受体阻滞剂比索洛尔的老年原发性高血压患者骨密度明显增高,骨折发生率下降,但血清钙代谢未受到影响。 Objective To observe the effect of beta-blocker, bisoprolol, on bone mineral density (BMD) and fracture rate of the elderly patients with hypertension. Methods 150 elderly male patients with hypertension were selected. The patients were divided into group treated with bisoprolol(85 cases,5 mg qd) and control group without bisoprolol(65 cases). The patients in the treatment group took bisoprolol more than 3 years. The serum levels of calcium, phosphorus and alka- line phosphatase,BMD and fracture rate were compared between two groups. Results There was no significant difference in serum levels of calcium,phosphorus and alkaline phosphatase between the 2 groups (P〉 0.05). There were 4 fracture cases in treatment group(fracture rate 4.7%) and 7 fracture cases in control group(fracture rate 10.8%). There was no significant statistical difference in fracture rate between the two groups (P 〉 0.05), although it was lower in treatment group than in control group. There was significant difference in BMD between before and after treatment with bisoprolol for 3 years in the treatment group[(1.04±0. 11) g/cm^2vs (1.49± 0.13) g/cm^2 , P 〈 0. 05]. There was significant difference in BMD between the 2 groups after 3 years of treatment[(1.06±0.12) g/cm^2 vs (1.49±0.13) g/cm^2, P 〈 0. 05]. Conclusion The BMD was obviously increased and the morbidity of fracture was reduced in the elderly patients with hypertension who have taken beta-blocker bisoprolol for a long time,but the serum calcium metabolism was not influenced.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2009年第9期716-718,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 高血压 骨质疏松 比索洛尔 骨密度 骨折 hypertension osteoporosis bisoprolol bone density fractures
  • 相关文献

参考文献6

  • 1Jose L,Perez C, Isabel j, et al. Effect of the antihypertensive treatment on the bone mineral density and osteoporotic fracture. Current Hypertension Reviews, 2005,1:61-66.
  • 2Bonnet N, Gadois C, McCloskey E, et al. Protective effect of β blockers in postmenopausa[ women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 2007, 40: 1209-1216.
  • 3和渝斌,郭晓东,刘立新,贺平.不同钙拮抗剂对老年原发性高血压患者骨代谢的影响[J].中华高血压杂志,2009,17(4):360-362. 被引量:14
  • 4Rejnmark L. Cardiovascular drugs and bone. Current Drug Safety, 2008,3 : 178-184.
  • 5Rejnmark L,Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. Journal of Hypertension, 2006,24 : 581-589.
  • 6Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature, 2005,434 : 514-520.

二级参考文献2

共引文献13

同被引文献57

  • 1李小珠,陈恩,冯佩兰.原发性高血压患者血压变化规律与自主神经功能的关系探讨[J].中国实用医药,2007,2(32):39-40. 被引量:6
  • 2Robinson TG,Carr SJ.Cardiovascular autonomic dysfunction in uremia.Kidney Int,2002,62(6):1921-1932.
  • 3Oikawa K,Ishihara R,Maeda T,et al.Prognostic value of heart rate variability in patients with renal failure on hemodialysis.Int J Cardiol,2009,131(3):370-377.
  • 4Manjunath G,Levey AS,Sarnak MJ.How can the cardiac death rate be reduced in dialysis patients?Semin Dial,2002,15(1):18-20.
  • 5Yamanaka N,Aoyama T,Ikeda N,et al.Characteristics of heart rate variability entropy and blood pressure during hemodialysis in patients with end-stage renal disease.Hemodial Int,2005,9(3):303-308.
  • 6Laaksonen S,Voipio-Pulkki L,Erkinjuntti M,et al.Doesdialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uraemia?J Intern Med,2000,248(1):21-26.
  • 7Tong YQ,Hou HM.Alteration of heart rate variability parameters in nondiabetic hemodialysis patients.Am J Nephrol,2007,27(1):63-69.
  • 8Port FK,Hulbert Shearon-TE,Wblfe RA,et al.Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysi patients.Am J Kindey Dis,1999,33(3):507-517.
  • 9Zager PG,Nikolic J,Brown RH,et al.U curve association of blood pressure and mortality in hemodialysis patients.Kidney Int,1998,54(2):561-569.
  • 10Agarwal R,Nissenson AR,Batlle D,et al.Prevalence,treatment,and control of hypertension in chronic hemodialysis patients in the United States.Am J Med,2003,115(4):291-297.

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部